

Client: Example Client ABC123

123 Test Drive

Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example** 

DOB 4/9/1986

Sex:

01234567890ABCD, 012345 **Patient Identifiers:** 

Female

**Visit Number (FIN):** 01234567890ABCD **Collection Date:** 01/01/2017 12:34

**HLA-DR Genotyping** 

ARUP test code 2002798

HLA Class II, Locus DRB1\*, Allele 1

07:01 DMMBZ

Performed By:

HLA Class II, Locus DRB1\*, Allele 2

11:04 CZXVZ Performed By:

**HLA-DR** Genotyping Interpretation

See Note

Performed By:

INTERPRETIVE INFORMATION: HLA DR GENOTYPING

PURPOSE: For immunization/vaccination trials or to aid the clinical diagnosis of diseases strongly associated with the

HLA-DR locus.
METHODOLOGY: PCR followed by Sequence Specific Oligonucleotide
Probe Hybridization of HLA-DR locus.
ANALYTICAL SENSITIVITY & SPECIFICITY: Medium to high resolution
of HLA-DR locus.

LIMITATIONS: The presence of a disease-associated HLA combination does not establish a diagnosis. If less than 2 alleles are reported for a locus, the patient is likely homozygous. Rare diagnostic errors can occur due to primer or probe site mutations. This test is not sufficient for comprehensive HLA evaluation for clinical hematopoietic stem cell transplantation; for pre-transplant allele matching, consider HLA Class I and II Panel (HLA A, HLA B, HLA C, DRB1, DQA1, DQB1, DPB1) by Next Generation Sequencing (ARUP test code 3002061) or HLA Class I and II Panel (HLA A, HLA B, HLA C, DRB1 DRB345, DQA1,DQB1, DPA1, DPB1) by Next Generation Sequencing

(ARUP test code 3002062). Occasionally the specific allele cannot be determined; in this case, the most likely allele assignment is made followed by a sequence of letters indicating other possible allele assignments. Interpretation of allele codes can be found at

https://bioinformatics.bethematchclinical.org/hla/alpha.v3.html.

H=High, L=Low, \*=Abnormal, C=Critical



Test systems were developed and their performance characteristics determined by the H&I laboratory at the University of Utah Health, under the accreditation guidelines from the American Society for Histocompatibility and Immunogenetics (ASHI).

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
HLA Class II, Locus DRB1*, Allele 1	22-118-133883	4/28/2022 12:59:00 PM	5/2/2022 7:34:42 AM	5/3/2022 1:41:00 PM
HLA Class II, Locus DRB1*, Allele 2	22-118-133883	4/28/2022 12:59:00 PM	5/2/2022 7:34:42 AM	5/3/2022 1:41:00 PM
HLA-DR Genotyping Interpretation	22-118-133883	4/28/2022 12:59:00 PM	5/2/2022 7:34:42 AM	5/3/2022 1:45:00 PM

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical